Abstract
This article presents an overview of the laboratory monitoring of the new direct anticoagulants (NDA) rivaroxaban, apixaban and dabigatran. Information regarding the intensity of anticoagunat activity may be provided by the Prothrombin Time (PT) for rivaroxaban and Activated Partial Thromboplastin Test (APTT) for dabigatran.
A more sensitive test during treatment with rivaroxaban or apixaban involves the Xa inhibition assay, preferably using calibration plasma with known contracentrations of the NDA. Use of the so-called calibrated diluted Thrombin Time is suitable for determining the actual contraception of dabigatran.